
|Articles|September 14, 2015
- Squamous NSCLC
- Volume 1
- Issue 1
Evolving Paradigms in Squamous NSCLC: Conclusion
Author(s)Staff Writer
Squamous cell lung cancer represents a distinct molecular pathologic NSCLC with unmet therapeutic needs, especially after failure of first-line platinum-based doublet chemotherapy.
Advertisement
This article is Part III of a series. View parts I and II:Evolving Paradigms in Squamous NSCLC> >
Articles in this issue
over 10 years ago
Cancer Immunotherapy: Evolving Treatment Options in Squamous NSCLCover 10 years ago
Evolving Paradigms in Squamous NSCLC: Referencesover 10 years ago
Evolving Paradigms in Squamous NSCLC: IntroductionAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5

















